Healwell AI's Hidden SpaceX Stake Adds Intrigue Ahead of Q1 Earnings

Healwell AI reports Q1 2026 on May 19, with a potential windfall from its xAI stake, a pure-play AI pivot, and the upcoming Amadeus platform launch driving growth.

A curious asset tucked away in Healwell AI's balance sheet is drawing fresh attention as the Canadian healthcare technology company prepares to deliver its first-quarter results next month. The firm originally invested $2 million into a vehicle tied to xAI, Elon Musk's artificial intelligence startup. When SpaceX acquired xAI in February, that stake suddenly transformed into an interest in the world's most valuable private company. Healwell is now exploring how to monetize that holding as part of a broader strategic review.

The potential windfall arrives at a pivotal moment. Healwell is deep into a dramatic transformation, shedding its clinical operations to emerge as a pure-play AI software business with recurring subscription revenue. The latest step in that process came in late March, when management signed a letter of intent to sell subsidiary HEAL Access Canada to AI Maverick Intel. Under the proposed terms, Healwell would receive 20 million exchangeable shares of the buyer plus a secured vendor note worth roughly $5 million. A binding agreement is targeted by May 29.

A Financial Turning Point

The numbers for fiscal 2025 tell the story of a company in transition. Revenue from continuing operations surged to C$103.8 million, a 427 percent jump from the prior year, fueled primarily by the acquisition of Orion Health that closed on April 1, 2025. More significantly, Healwell posted its first-ever full-year positive adjusted EBITDA of C$2.3 million. The fourth quarter alone swung from a loss of C$5 million to a gain of C$1.4 million, marking three consecutive profitable quarters by that measure.

The IFRS net loss, however, stood at C$39.1 million. Healwell is profitable on management's own scorecard, but not yet under standard accounting rules.

Earlier divestitures in the fourth quarter of 2025 brought in roughly C$9.7 million in cash, providing additional financial flexibility as the company focuses on its core AI platform.

Amadeus AI Takes Center Stage

The commercial engine of Healwell's new strategy is Amadeus AI, a unified platform that combines its earlier products Khure and Pentavere under a single artificial intelligence engine. The system draws on data from more than 150 million patient records to support clinical decision-making and early disease detection.

The North American launch is scheduled for the first half of 2026, with international expansion planned for late in the year. Healwell already manages health data networks across 11 countries and recently secured a multi-year, multi-million-dollar contract in the U.S. health information exchange segment.

Management has set ambitious targets for the current year: roughly 50 percent growth in AI-related revenue and an adjusted EBITDA margin of about 10 percent.

The First Real Test

Healwell will report its first-quarter 2026 numbers on May 19. The company has already flagged that this will be the weakest quarter of the year, citing seasonal demand patterns that typically weigh on Q1 performance.

Stifel responded by cutting its price target to C$2.50 from C$3.10, though the analyst maintained a Buy rating. The broader Wall Street consensus remains more optimistic at an average target of C$3.61.

The stock has shown resilience despite the lowered target. Trading in Frankfurt at €0.59, the shares have climbed roughly 24 percent over the past month and moved decisively above their 50-day moving average. They remain about 43 percent below their 52-week high but have recovered significantly from the February trough.

The upcoming earnings report will provide the first hard evidence of whether Healwell's profit streak can continue and whether Amadeus AI is gaining commercial traction. For a company juggling a hidden SpaceX stake, a portfolio overhaul, and a make-or-break product launch, the stakes could hardly be higher.